IGFBP levels measured by RIA were increased by growth hormone treatment (178.9 ± 4.9 ng/ml) 10 and decreased after fasting (95.0 ± 7.0 ng/ml). The molarities of plasma 41-kDa IGFBP and total 11 IGF-I were comparable, and they were positively correlated, suggesting that salmon 41-kDa IGFBP 12 is a main carrier of circulating IGF-I in salmon, as is mammalian IGFBP-3 in mammals. During 13 the parr-smolt transformation (smoltification) of coho salmon, plasma 41-kDa IGFBP levels 14 showed a transient peak (182.5 ± 10.3 ng/ml) in March and stayed relatively constant thereafter, 15
has a molecular weight similar to mammalian IGFBP-3 and its plasma levels are influenced by 26 growth hormone treatment and fasting as is mammalian IGFBP-3 (Shimizu et al., 1999). We 1 recently purified the salmon 41-kDa IGFBP from serum (Shimizu et al., 2003) and generated 2 specific antibody against it. Using this antibody and purified protein as assay components, we 3 developed a radioimmunoassay for salmon 41-kDa IGFBP. 4 described in Shimizu et al. (2003) . Briefly, salmon serum was acidified with 2 M acetic acid, 0.75
Preparation of tracers 11
Purified 41-kDa IGFBP was iodinated with 0.5 mCi Na 125 I (Amersham Life Sicence Inc.) 12 by chloramine-T method as described in Moriyama et al. (1994) . Five micrograms of the 41-kDa 13 IGFBP in 36 µl was mixed with 64 µl 0.5 M phosphate buffer, pH 7.4. The mixture was reacted 14 with 20 µl of 0.4 mg/ml chloramine-T (Sigma; St. Louis, MO, USA ) for 90 sec and 20 µl of 0.6 15 mg/ml metabisulfite was added to stop the reaction. Iodinated 41-kDa IGFBP (IGFBP*) was 16 separated from free Na 125 I using Biogel P-6 (1 x 18 cm; Bio-Rad). Specific activity of the tracer 17 estimated by the self-displacement assay (Catt, 1976) was 29.8 µCi/µg. 18 Sephadex G-50 (1 x 18 cm, superfine; Pharmacia, Uppsala, Sweden). Specific activity of the tracer 23 was 49.2 µCi/µg. 24 A tracer consisting of unlabelled 41-kDa IGFBP and 125 I-salmon IGF-I was also prepared. 25
Salmon IGF-I was iodinated by the chloramine-T method as described above and an aliquot of 26 125 I-salmon IGF-I (1 µg) was incubated with 6.7 µg purified 41-kDa IGFBP for 2 hr, and they 1 were cross-linked by disuccinimidyl suberate. The 41-kDa IGFBP cross-linked with 125 I-salmon 2 IGF-I (IGFBP/IGF-I*) was separated from non-reacted 125 I-salmon IGF-I by gel filtration using 3 Sephadex G-50. Specific activity of the tracer was 6.6 µCi/µg. 4
5
Radioimmunoassay for 41-kDa IGFBP 6
Radioimmunoassay was carried out in 12 x 75 mm polystyrene test tubes. Purified 41-kDa 7 IGFBP was used for the standard. One hundred microliters of standard or plasma diluted in 20 8 mM phosphate, 150 mM NaCl containing 1.0% bovine serum albumin and 0.05% Triton X-100 9
were incubated with 100 µl anti-41-kDa IGFBP at a dilution of 1:3000-5000 overnight at 4°C. 10
Approximately 7000 cpm of tracer in 100 µl was added to the tubes and incubated overnight at 4°C. 11
Free and antibody-bound tracers were separated by the addition of 0.5% Pansorbin (Calbiochem-12 Novabiochem Corp., La Jolla, CA, USA). After incubating overnight at 4°C, tubes were centrifuged 13 at 1350g for 30 min and the supernatant was aspirated. Radioactivity in the pellets was measured 14 by a gamma counter (Packard, Meriden, CT, USA). 15 IGF-I was extracted from plasma by acid-ethanol followed by cryoprecipitation according 18 to the method of Breier et al. (1991) . This extraction method has been validated for salmon plasma 19 (Shimizu et al., 2000) . IGF-I was measured by RIA as described in Shimizu et al. (2000) . 20
21

Statistical analysis 22
Results of the experiments were analyzed using one-way ANOVA followed by the Fisher 23 protected least-significant difference test (Dowdy & Weardon, 1991) using the Statview 512+ 24 program (Abacus Concepts, Inc., Berkeley, CA, USA). Differences between groups were 25 considered to be significant at P < 0.05. 26
Results
1
Specificity of a polyclonal antiserum against salmon 41-kDa IGFBP was assessed by 2 immunoblotting of purified and semi-purified salmon IGFBPs (Fig. 1) . Anti-41-kDa IGFBP 3 immunostained doublet bands at 43 and 41 kDa in the purified 41-kDa IGFBP fraction. Doublet 4 bands at higher molecular weight, presumably aggregation of the 43-41 kDa doublet bands, were 5 also recognized by the antiserum. Anti-41-kDa IGFBP cross-reacted with 28-kDa IGFBP weakly 6 but not with 22-kDa IGFBP. This antiserum was used for RIA of salmon 41-kDa IGFBP. 7
Three differently prepared tracers were examined for development of the RIA; purified 41-8 kDa IGFBP directly labelled with I-125 (IGFBP*), labelled 41-kDa IGFBP cross-linked with 9 unlabelled salmon IGF-I (IGFBP*/IGF-I), and unlabelled 41-kDa IGFBP cross-linked with 10 labelled salmon IGF-I (IGFBP/IGF-I*). All three tracers bound specifically to the antiserum and 11
were displaced with unlabelled 41-kDa IGFBP in a concentration-dependent manner albeit total 12 binding differed among tracers (Fig. 2) . The tracers were next compared for interaction with added 13 salmon IGF-I with and without the addition of 10 ng/ml unlabelled 41-kDa IGFBP (Fig. 3) . When 14 the combination of unlabelled IGF-I and 41-kDa IGFBP was added to the tracers, the percent of 15 tracer bound increased for IGFBP* and IGFBP*/IGF-I, but remained constant for IGFBP/IGF-I*. 16
Thus, added IGF-I in excess of 2 ng/ml reduced the displacement of two of the tracers. Total 17 binding of two of the tracers (IGFBP* and IGFBP/IGF-I*) was not affected by added IGF-I, but 18 the total binding of IGFBP*/IGF-I was increased slightly when IGF-I was added at 10 ng/ml or 19 greater (Fig. 3) . Therefore, IGFBP/IGF-I* was used as the tracer in the RIA. 20
Using the IGFBP/IGF-I* as tracer, specific and non-specific binding to the antiserum 21
(1:3000 dilution) under the assay conditions were 20.83 ± 0.78% (mean ± SEM; n = 8) and 0.81 22 ± 0.04% (n = 8), respectively. The half-maximal displacement (ED 50 ) occurred at 10.01 ± 0.23 23 ng/ml (n = 8). The ED 80 and ED 20 were 3.43 ± 0.13 ng/ml and 27.13 ± 0.96 ng/ml (n = 8), 24 respectively. The minimal detection limits of the assay, defined as the mean of the zero standard 25 minus two standard deviations, was 0.44 ± 0.07 ng/ml (n = 8). The precision profile (Ekins, 1983) 26 of the standard curve indicate that the functional sensitivity, defined as the concentration at which 1 the inter-assay coefficients of variation is ≤ 20% (Spencer et al., 1995), was 1.56 ng/ml (n = 10). 2
The intra-and inter-assay coefficients of variation estimated at 8.85 ng/ml using a control serum 3 were 3.6% (n = 10) and 11.3% (n = 5), respectively. Recovery of purified 41-kDa IGFBP added to 4 chinook salmon serum was 91.9 ± 4.5% (n = 3). 5
In order to further assess possible interference by IGFs in the RIA, the slopes of the 6 IGFBP standards with or without adding IGFs were compared (Fig. 4) . Addition of unlabelled 7 sIGF-I up to 1:100 molar ratio did not affect the slope of the standard, and it was parallel to that of 8 salmon serum. Similar results were obtained with human IGF-I and IGF-II (data not shown). 9
Next, the effect of addition of IGFs to plasma on measured 41-kDa IGFBP was examined (Table  10 1). There was no statistical difference in measured plasma 41-kDa IGFBP with or without IGFs. 11
Coho salmon plasma from fish in different physiological states showed parallel 12 displacement with the standard (Fig. 5) . There was no difference in slope and binding of 13 displacement curve between plasma and serum from coho salmon (data not shown). No 14 displacement was observed with a partially purified salmon 28-kDa IGFBP containing 22-kDa 15 IGFBP as a minor component. 16
Plasma levels of 41-kDa IGFBP in coho salmon from GH-injection and fasting 17 experiments were measured by RIA. GH-treatment caused a significant increase of plasma 41-kDa 18 IGFBP levels whereas fasting reduced plasma 41-kDa IGFBP levels (Fig. 6 ). There was a strong 19 positive relationship between total IGF-I and 41-kDa IGFBP levels in individual samples (Fig. 7a) . 20
The correlation coefficient was higher with an exponential regression (r 2 = 0.85) than with a linear 21 regression (r 2 = 0.78). A weaker, but significant, relationship was found between free IGF-I and 22 41-kDa IGFBP (Fig. 7b) . The relationship was best represented by a polynomial regression (r 2 = 23 0.61). 24
Changes in plasma IGF-I and 41-kDa IGFBP levels during smoltification of coho salmon 25
were measured by RIAs (Fig. 8) . The condition factor, a morphological index of smoltification, 26 declined from mid March to its lowest point in early May indicating the completion of 1 smoltification (data not shown). Plasma IGF-I exhibited peaks in mid March and late April (Fig.  2   8) . Plasma 41-kDa IGFBP, on the other hand, showed a transient peak in late March, 3 corresponding to the first peak of IGF-I, and stayed relatively constant thereafter (Fig. 8) . availability. However, we did not measure free IGF-I levels, which is believed to be a biologically 20 active form available to the receptor, nor other IGFBP levels in those fish. In order to fully 21 understand regulation of salmon smoltification by the GH-IGF-I axis including IGFBPs, more 22 detailed studies are needed. 23
In conclusion, we established a radioimmunoassay for salmon 41-kDa IGFBP. human IGF-I 1 103.5 ± 11.1 10 102.0 ± 9.7 100 108.7 ± 11.7
human IGF-II 1 110.9 ± 13.5 10 107.6 ± 11.7 100 104.0 ± 11.0
Data are expressed as mean ± S.E., n = 5
